News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
276,443 Results
Type
Article (8964)
Company Profile (25)
Press Release (267454)
Section
Business (96328)
Career Advice (1055)
Deals (17398)
Drug Delivery (27)
Drug Development (32634)
Employer Resources (41)
FDA (5654)
Job Trends (5494)
News (151046)
Policy (10180)
Tag
Academia (564)
Alliances (17358)
Alzheimer's disease (397)
Antibody-drug conjugate (ADC) (43)
Approvals (5649)
Artificial intelligence (42)
Bankruptcy (117)
Best Places to Work (4336)
Breast cancer (96)
Cancer (651)
Cardiovascular disease (45)
Career advice (836)
CAR-T (46)
Cell therapy (135)
Clinical research (27067)
Collaboration (175)
Compensation (103)
COVID-19 (748)
C-suite (78)
Data (659)
Diabetes (57)
Diagnostics (2545)
Earnings (46040)
Events (44300)
Executive appointments (279)
FDA (5933)
Funding (173)
Gene therapy (75)
GLP-1 (247)
Government (892)
Healthcare (6775)
Infectious disease (773)
Interviews (179)
IPO (8982)
Job creations (1310)
Job search strategy (748)
Layoffs (152)
Legal (2576)
Lung cancer (93)
Lymphoma (60)
Manufacturing (66)
Medical device (5231)
Medtech (5232)
Mergers & acquisitions (8544)
Metabolic disorders (187)
Neuroscience (527)
NextGen Class of 2024 (2246)
Non-profit (1246)
Northern California (866)
Obesity (105)
Opinion (79)
People (29025)
Phase I (8678)
Phase II (11634)
Phase III (9509)
Pipeline (366)
Postmarket research (906)
Preclinical (2687)
Press Release (67)
Radiopharmaceuticals (131)
Rare diseases (104)
Real estate (2134)
Regulatory (7180)
Research institute (575)
Resumes & cover letters (191)
Southern California (674)
Startups (1259)
United States (6685)
Vaccines (148)
Weight loss (72)
Date
Last 7 days (83)
Last 30 days (738)
Last 365 days (15502)
2025 (42)
2024 (15843)
2023 (17963)
2022 (23768)
2021 (25174)
2020 (23122)
2019 (17624)
2018 (13320)
2017 (13293)
2016 (11875)
2015 (15115)
2014 (11625)
2013 (9200)
2012 (9875)
2011 (10412)
2010 (9864)
Location
Africa (285)
Arizona (54)
Asia (16117)
Australia (2603)
California (1813)
Canada (660)
China (113)
Colorado (75)
Connecticut (95)
Europe (34262)
Florida (217)
Georgia (49)
Illinois (137)
Indiana (77)
Japan (61)
Maryland (204)
Massachusetts (1350)
Michigan (72)
Minnesota (144)
New Jersey (536)
New York (467)
North Carolina (322)
Northern California (866)
Ohio (63)
Pennsylvania (380)
South America (424)
Southern California (674)
Texas (225)
Utah (54)
Washington State (164)
276,443 Results for "i3 corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.
June 20, 2024
·
2 min read
Press Releases
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
November 1, 2024
·
1 min read
Press Releases
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
December 29, 2024
·
6 min read
Press Releases
Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson
September 9, 2024
·
4 min read
Press Releases
B2i Digital Confirmed as Marketing Partner for the 3rd Annual ROTH Healthcare Opportunities Conference
September 19, 2024
·
2 min read
Press Releases
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
September 30, 2024
·
8 min read
BoomRay’s Radioactive Diagnostic New Drug [18F]BF3-BPA Injection Completes First Subject Enrollment in Phase I Clinical Trial
BoomRay Pharmaceutical Co., Ltd. (“BoomRay”) announced that the phase I clinical trial of its positron emission tomography (PET) tracer [18F]BF3-BPA injection for the diagnosis of primary and metastatic brain tumors has completed the enrollment of the first subject.
April 22, 2024
·
2 min read
Drug Development
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
Vividion Therapeutics, Inc., announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.
February 6, 2024
·
6 min read
Press Releases
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
December 6, 2024
·
6 min read
Press Releases
Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa
September 13, 2024
·
8 min read
1 of 27,645
Next
